Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis

[1]  B. Falissard,et al.  Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study , 2020, Dermatology and Therapy.

[2]  L. Nelson,et al.  Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT) , 2019, Current medical research and opinion.

[3]  A. Armstrong,et al.  Association Between Atopic Dermatitis and Suicidality: A Systematic Review and Meta-analysis , 2019, JAMA dermatology.

[4]  S. Feldman,et al.  Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis , 2018, JAMA dermatology.

[5]  D. Margolis,et al.  Epidemiology of atopic dermatitis in adults: Results from an international survey , 2018, Allergy.

[6]  T. Mustelin,et al.  Serum biomarker profiles suggest that atopic dermatitis is a systemic disease. , 2018, The Journal of allergy and clinical immunology.

[7]  H. Williams,et al.  Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative) , 2016, The British journal of dermatology.

[8]  M. Ardeleanu,et al.  P480 Correlations of itch with quality of life and signs of atopic dermatitis across dupilumab trials , 2017 .

[9]  G. Girolomoni,et al.  The Patient-Reported Disease Burden In Adults With Atopic Dermatitis: A Cross-Sectional Study In Canada and Europe , 2017 .

[10]  J. Piercy,et al.  Discordance Between Physician- and Patient-Reported Disease Severity in Adults with Atopic Dermatitis: A US Cross-Sectional Survey , 2017, American Journal of Clinical Dermatology.

[11]  D. Leung,et al.  Assessing the current treatment of atopic dermatitis: Unmet needs. , 2017, The Journal of allergy and clinical immunology.

[12]  J. Silverberg,et al.  Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder. , 2017, The Journal of investigative dermatology.

[13]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[14]  B. Emir,et al.  The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey , 2016, Current medical research and opinion.

[15]  T. Bieber,et al.  Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. , 2016, Journal of the American Academy of Dermatology.

[16]  Simon A Naji,et al.  Health measurement scales: a practical guide to their development and use (5th edition). , 1990, Australian and New Zealand journal of public health.

[17]  Ralf Dresner,et al.  Health Measurement Scales A Practical Guide To Their Development And Use , 2016 .

[18]  Jody L. Vogelzang,et al.  Health Measurement Scales: A Practical Guide to Their Development and Use , 2015 .

[19]  D. Margolis,et al.  Atopic dermatitis disease control and age: A cohort study. , 2015, The Journal of allergy and clinical immunology.

[20]  A. Finlay,et al.  Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data , 2015, Dermatology.

[21]  L. Misery,et al.  The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries , 2014, The Journal of investigative dermatology.

[22]  Masutaka Furue,et al.  The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. , 2014, The Journal of allergy and clinical immunology.

[23]  A. Alomar,et al.  Dermatitis atópica desde la perspectiva del paciente: desencadenantes, cumplimiento de las recomendaciones médicas y control de la enfermedad. Estudio DATOP , 2014 .

[24]  S. Feldman,et al.  Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. , 2014, Journal of the American Academy of Dermatology.

[25]  H. Nakagawa,et al.  Impact of disease severity on work productivity and activity impairment in Japanese patients with atopic dermatitis , 2013, The Journal of dermatology.

[26]  H. Williams,et al.  Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting , 2012, Allergy.

[27]  M. Boguniewicz,et al.  Atopic dermatitis: a disease of altered skin barrier and immune dysregulation , 2011, Immunological reviews.

[28]  J. Krueger,et al.  Contrasting pathogenesis of atopic dermatitis and psoriasis--part I: clinical and pathologic concepts. , 2011, The Journal of allergy and clinical immunology.

[29]  S. Reitamo,et al.  Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: Results from two randomized, multicentre, comparative studies , 2010, The Journal of dermatological treatment.

[30]  T. Bieber.  Invited Review Article : Atopic Dermatitis , 2010 .

[31]  T. Bieber.  Atopic dermatitis. , 2010, Annals of dermatology.

[32]  J. Durlak.  How to select, calculate, and interpret effect sizes. , 2009, Journal of pediatric psychology.

[33]  Donald Y M Leung,et al.  Disease severity, scratching, and sleep quality in patients with atopic dermatitis. , 2008, Journal of the American Academy of Dermatology.

[34]  M. Meurer,et al.  The Role of Pimecrolimus Cream 1% (Elidel®) in Managing Adult Atopic Eczema , 2007, Dermatology.

[35]  C. Terwee,et al.  Quality criteria were proposed for measurement properties of health status questionnaires. , 2007, Journal of clinical epidemiology.

[36]  U. S. Department of Health and Human Services FDA Cen Research,et al.  Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance , 2006, Health and quality of life outcomes.

[37]  Torsten Zuberbier,et al.  Patient perspectives on the management of atopic dermatitis. , 2006, The Journal of allergy and clinical immunology.

[38]  A. Finlay,et al.  Translating the science of quality of life into practice: What do dermatology life quality index scores mean? , 2005, The Journal of investigative dermatology.

[39]  H. Williams,et al.  The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. , 2004, Archives of dermatology.

[40]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[41]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[42]  J. M. Cortina,et al.  What Is Coefficient Alpha? An Examination of Theory and Applications , 1993 .

[43]  Julia Brasch,et al.  Severity Scoring of Atopic Dermatitis: The SCORAD Index , 1993 .

[44]  A. Taïeb,et al.  Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. , 1993, Dermatology.

[45]  Jacob Cohen,et al.  A power primer. , 1992, Psychological bulletin.

[46]  D. Streiner,et al.  Health Measurement Scales: A practical guide to thier development and use , 1989 .

[47]  I I Lelis,et al.  [Atopic dermatitis]. , 1980, Vestnik dermatologii i venerologii.

[48]  J. Fleiss,et al.  Intraclass correlations: uses in assessing rater reliability. , 1979, Psychological bulletin.